| HALOZYME THERAPEUTICS |
| USA |
| Gesundheit |
| US40637H1095 / A0DLHS |
| RV7 (Frankfurt) / HALO (NASDAQ) |
| FRA:RV7, ETR:RV7, RV7:GR, NASDAQ:HALO |
| - |
| https://halozyme.com/ |
|
Halozyme Therapeutics Inc. is a biopharmaceutical technology company focused on drug delivery solutions and specialty medicines. Its core platform, ENHANZE, uses the proprietary enzyme rHuPH20 to help enable subcutaneous delivery of injectable therap..
>Volltext.. |
| 13279.23 Mio. EUR |
| 14969.77 Mio. EUR |
| 1493.45 Mio. EUR |
| 950.95 Mio. EUR |
| 371.26 Mio. EUR |
| 3.16 EUR |
| 1926.94 Mio. EUR |
| 146.44 Mio. EUR |
| 734.81 Mio. EUR |
| 0.67 |
| 45.59% |
| -23.45% |
| - |
| - |
| - |
| - |
| HALOZYME |
| 09.11.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|